Article

Body Mass Index Adjusted Prostate-specific Antigen and Its Application for Prostate Cancer Screening

University of Texas Health Science Center at Houston, Houston, Texas, United States
Urology (Impact Factor: 2.13). 11/2010; 76(5):1268.e1-6. DOI: 10.1016/j.urology.2010.04.060
Source: PubMed

ABSTRACT The prostate cancer prevention trial (PCPT) prostate cancer risk calculator was developed to aid physicians in counseling men for consideration of prostate biopsy based on prostate-specific antigen (PSA) and other clinical risk factors. This study investigated the role of body mass index (BMI) in this assessment.
BMI category was defined as < 25 (under/normal weight), 25.0-29.9 (overweight), 30.0-34.9 (obese [OB] I), 35.0-39.9 (OB II), and ≥ 40 (OB III). BMI-adjusted PSA for a man was determined by multiplying his PSA to the ratio of the geometrical mean of PSA for BMI < 25 to the geometrical mean of PSA for his BMI category. Operating characteristics of PSA and BMI-adjusted PSA were compared with PCPT risks using area underneath the receiver operating characteristic curve (AUC). Statistical tests of differences between AUCs for different diagnostic tests were performed with the nonparametric U-statistic method.
BMI-adjusted PSA equaled to unadjusted PSA multiplying 1.09, 1.20, 1.50, and 1.71 for men in overweight, OBI, OBII, and OBIII categories, respectively. The AUC for BMI-adjusted PSA values (0.84) did not differ from PSA; that of the PCPT calculator with BMI-adjusted PSA (0.87) did not differ from the calculator with PSA. Of 2816 men with a PSA less than or equal to 2.5 ng/mL who did not undergo biopsy, 126 (4.5%) would have a BMI-adjusted PSA exceeding 2.5 ng/mL.
Because of lower levels of PSA, overweight and obese men may have diminished cancer detection opportunities when undergoing PSA-based screening.

0 Bookmarks
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the role of body mass index (BMI) in assessment of prostate cancer (PCa) risk. 3,258 participants who underwent biopsy (including 1,902 men with a diagnosis of PCa) were identified from the Selenium and Vitamin E Cancer Prevention Trial. The associations of BMI with PCa and high-grade PCa (HGPCa) were examined using logistic regression, adjusting for age, race, BMI-adjusted prostate-specific antigen, digital rectal exam, family history of PCa, previous biopsy history, PSA velocity and time between study entry and the last biopsy. The prediction models were compared with our previously-developed BMI-adjusted Prostate Cancer Prevention Trial prostate cancer Risk Calculator (bmiPCPTRC). Of the study subjects, 49.1% were overweight and 29.3% were obese. After adjustment, among men without a known family history of PCa, increased BMI was not associated with higher risk of PCa (per one-unit increase in logBMI: OR=0.83, p=0.54) but was significantly associated with higher risk of HGPCa (i.e., Gleason score≥7 prostate cancer) (OR=2.31, p=0.03). For men with a known family history of PCa, the risks of PCa and HGPCa increased rapidly as BMI increased (PCa: OR=3.73, p=0.02; HGPCa: OR=7.95, p=0.002). The bmiPCPTRC generally underestimated the risks of PCa and HGPCa. BMI provided independently predictive information regarding risks of PCa and HGPCa, after adjusting for other risk factors. BMI, especially among men with a known family history of PCa, should be considered for inclusion in any clinical assessment of PCa risk and recommendations regarding prostate biopsy.
    The Journal of urology 04/2014; 192(4). DOI:10.1016/j.juro.2014.04.015 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND:It remains unclear whether the hemodilution effect of body mass index (BMI) on PSA levels translates to inappropriate prostate cancer (PCa) screening in obese men. To address this, we conducted two nested case-control studies within prospective cohorts of men undergoing radical prostatectomy for newly diagnosed PCa.METHODS:We identified 1817 men with BMI 30 kg m(-2) (cases) and 1244 men with BMI <25 kg m(-2) (controls) who underwent surgery to treat PCa at Mayo Clinic in Rochester between 2000 and 2009. Cases and controls were frequency matched on age and PSA level. In a similar manner, we identified 206 cases and 133 controls treated at Mayo Clinic in Florida between 2006 and 2011. We employed logistic regression models to evaluate the association of pathologic features of aggressiveness with obesity status.RESULTS:After adjusting for age and PSA level, we noted that obese men in the Rochester population are more likely to present with Gleason grade 8-10 tumors (OR= 1.50; 95% CI 1.14-1.96; P=0.003) and pT3, pT4, pTxN+ stage disease (OR=1.30; 95% CI 1.05-1.62). We noted a similar association seminal vesicle involvement (OR= 1.41; 95% CI 1.03-1.92; P=0.03). Results from the smaller Florida population supported these same associations but did not achieve conventional statistical significance.CONCLUSIONs:Obese men present with more aggressive PCa tumors compared with non-obese men of similar age and PSA screening values. If confirmed, this would support the need to explore PSA-based screening in obese men to possibly account for a hemodilution effect.Prostate Cancer and Prostatic Disease advance online publication, 20 August 2013; doi:10.1038/pcan.2013.27.
    Prostate cancer and prostatic diseases 08/2013; DOI:10.1038/pcan.2013.27 · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between metabolic syndrome (MS) and prostate cancer (PCA) is highly complex and harbors multiple facets not least because MS is not a single entity but represents a poorly defined inhomogeneous mixture of different diseases and conditions. Although numerous studies suggest a correlation between MS or components of MS and the development of prostate cancer, current evidence cannot be considered convincing. While diabetes appears to be inversely related to PCA, increased serum levels of triglycerides, cholesterol and insulin-like growth factor 1 (IGF-1) may be predictive for high grade disease. Further studies suggested that MS and high serum insulin levels are independent predictors of an unfavorable prognosis in patients with metastatic PCA. Early detection and improved therapeutic options have dramatically prolonged the course of the disease in advanced PCA through the last decades. As a consequence, development of MS in patients undergoing hormone therapy along with the cardiovascular risks has gained increasing relevance. Based on this evolution prevention, early detection and sustainable therapy represent an important clinical challenge to modern urologists active in urooncology.
    Der Urologe 03/2013; DOI:10.1007/s00120-013-3135-3 · 0.44 Impact Factor

Preview

Download
0 Downloads
Available from